

Beacon Award for Women Leaders in Oncology

2025 Call for Nominations

Deadline:

May 31, 2025

The AIM-HI Beacon Award for Women Leaders in Oncology

The AIM-HI Beacon Award for Women Leaders in Oncology recognizes outstanding women leaders in all sectors of the health and life science industry, who have made a significant impact on advancing cancer treatment, detection, and diagnosis for patients worldwide, through the development and commercialization of novel technologies, advocacy, and/or implementation of public policy.

The 2025 AIM-HI Beacon Award recipient will be awarded an authentic gold medal and honored at a Luncheon Award Ceremony at the National Press Club in Washington, DC on October 24, 2025.

To Submit Your Nomination:

- Nominations are submitted by an online form at <u>AIM-Hlaccelerator.org/Nominate</u>
- Please submit all required documents.
- The Award Selection Committee reviews all complete submissions.

The AIM-HI Beacon Award for Women Leaders in Oncology

Nominations

Nominees will have played an essential role in helping develop, approve and commercialize innovative cancer drugs, therapies or diagnostics and that are impacting patients' lives or have significant promise to do so in the future. Two conominees may be considered if they demonstrate shared leadership responsibilities for the development of oncology discoveries, technologies and/or products.

Nominations from academia, the investment community, industry, government, or other organizations are welcome and require:

- Nominee's CV (ten pages maximum) containing employment history, previous honors/awards and contact information (including cell phone)
- A Letter of Nomination (no more than 2,000 words) describing the Nominee's success, barriers she overcame, contributions and impact she has made for cancer patients from commercialization of technology, product, and/or public policy. The letter should indicate the Nominator's position and brief biographical information
- Nomination closes on May 31, 2025

The AIM-HI Beacon Award for Women Leaders in Oncology

Award Selection Process

All nomination information will be kept confidential, and be reviewed and evaluated by the distinguished AIM-HI Beacon Award Selection Committee, comprising of physician-scientists, successful entrepreneurs, and prominent business leaders in the health & life sciences industry.

Nominations will be assessed according to the following criteria:

- Sustained commitment and leadership for cancer research, development and commercialization of innovative products
- Advocacy for and implementation of public policy to benefit cancer patients
- Encouragment, advocacy and inspiration of other women
- Impact on cancer patients, their families and community

The Selection Committee will carefully consider the merit and impact all the nominees and select the most deserving awardee(s) each year.

The AIM-HI Beacon Award Previous Awardees



Margaret Foti, Ph.D., M.D. (hc)

2024 Awardee
Chief Executive Officer
American Association for Cancer Research



Monica M. Bertagnolli, M.D.

2023 Awardee
Director
National Cancer Institute



Anna D. Barker, Ph.D.

2022 Awardee

Chief Strategy Officer, Lawrence J. Ellison
Institute for Transformative Medicine;
Distinguished Visiting Fellow, Complex
Adaptive Systems, Arizona State University



About the AIM-HI Accelerator Fund

The AIM-HI Accelerator Fund (AIM-HI) is a 501(C)(3) non-profit organization, created in 2019 by the National Foundation for Cancer Research to provide oncology startups with the resources they need to drive innovative discoveries forward, out of the lab, to the clinics, and eventually to the people battling cancer. Our mission is to bridge the gap between research breakthroughs and clinical trials, with the ultimate goal of developing innovative cancer therapies and technologies that can save patients' lives.

A TAX EXEMPT CHARITY
TAX ID#: 82-4322538
5515 Security Lane, Suite 1105
Rockville, MD 20852
www.AIM-Hlaccelerator.org